Diabetes - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols TCTN2 and COQ5	Name 1 tectonic family member 2	Name2 coenzyme Q5, methyltransferase	Pathway 1 Anchoring of the basal body to the plasma membrane	Pathway 2 Ubiquinol biosynthesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols IFT80 and OTOL1	Name 1 intraflagellar transport 80	Name2 otolin 1	Pathway 1 Intraflagellar transport Intraflagellar transport	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols PHACTR2 and G3BP2	Name 1 phosphatase and actin regulator 2	Name2 G3BP stress granule assembly factor 2	Pathway 1 Platelet degranulation	Pathway 2 SARS-CoV-2 activates/modulates innate and adaptive immune responses	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CILP2 and NIBAN3	Name 1 cartilage intermediate layer protein 2	Name2 niban apoptosis regulator 3	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FREM2 and NHLRC3	Name 1 FRAS1 related extracellular matrix 2	Name2 NHL repeat containing 3	Pathway 1	Pathway 2 Neutrophil degranulation	Drugs 1	Drugs 2	Diseases 1 Fraser syndrome	Diseases 2
Novel Novel	Symbols DNAH5 and LARGE1	Name 1 dynein axonemal heavy chain 5	Name2 LARGE xylosyl- and glucuronyltransferase 1	Pathway 1	Pathway 2 Defective LARGE causes MDDGA6 and MDDGB6 Matriglycan biosynthesis on DAG1	Drugs 1	Drugs 2	Diseases 1 Primary ciliary dyskinesia, including: Primary ciliary dyskinesia; Kartagener syndrome	Diseases 2 Dystroglycanopathy; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama congenital muscular dystrophy (FCMD); Congenital muscular dystrophy with muscle hypertrophy (MDC1C); Congenital muscular dystrophy with severe intellectual impairment and abnormal glycosylation (MDC1D) Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
Novel Novel	Symbols TMEM127 and LMAN2L	Name 1 transmembrane protein 127	Name2 lectin, mannose binding 2 like	Pathway 1	Pathway 2 COPII-mediated vesicle transport Cargo concentration in the ER	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols TTC9 and SMOC1	Name 1 tetratricopeptide repeat domain 9	Name2 SPARC related modular calcium binding 1	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols NKX6-3 and IDO2	Name 1 NK6 homeobox 3	Name2 indoleamine 2,3-dioxygenase 2	Pathway 1	Pathway 2 Tryptophan catabolism	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols LVRN and FAM170A	Name 1 laeverin	Name2 family with sequence similarity 170 member A	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ZNF799 and TIMM29	Name 1 zinc finger protein 799	Name2 translocase of inner mitochondrial membrane 29	Pathway 1 Generic Transcription Pathway	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols WSCD2 and CKAP4	Name 1 WSC domain containing 2	Name2 cytoskeleton associated protein 4	Pathway 1	Pathway 2 Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Surfactant metabolism Neutrophil degranulation Post-translational protein phosphorylation RND3 GTPase cycle RND2 GTPase cycle	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols GCK and PFKFB2	Name 1 glucokinase	Name2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2	Pathway 1 Regulation of Glucokinase by Glucokinase Regulatory Protein Regulation of gene expression in beta cells Defective GCK causes maturity-onset diabetes of the young 2 (MODY2) Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) Glycolysis FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	Pathway 2 Regulation of glycolysis by fructose 2,6-bisphosphate metabolism	Drugs 1 Beta-D-Glucose 2-amino-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide 3-[(4-fluorophenyl)sulfanyl]-N-(4-methyl-1,3-thiazol-2-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide 2-(methylamino)-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide 2-AMINO-4-FLUORO-5-[(1-METHYL-1H-IMIDAZOL-2-YL)SULFANYL]-N-(1,3-THIAZOL-2-YL)BENZAMIDE	Drugs 2	Diseases 1 Permanent neonatal diabetes mellitus (PNDM) Maturity onset diabetes of the young (MODY)	Diseases 2
Novel Novel	Symbols GATA2 and HHEX	Name 1 GATA binding protein 2	Name2 hematopoietically expressed homeobox	Pathway 1 RUNX1 regulates transcription of genes involved in differentiation of HSCs Transcriptional regulation of granulopoiesis Factors involved in megakaryocyte development and platelet production	Pathway 2 Developmental Lineage of Multipotent Pancreatic Progenitor Cells	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Type II diabetes mellitus
Novel Novel	Symbols ALDOA and ERBB3	Name 1 aldolase, fructose-bisphosphate A	Name2 erb-b2 receptor tyrosine kinase 3	Pathway 1 Platelet degranulation Neutrophil degranulation Glycolysis Gluconeogenesis	Pathway 2	Drugs 1 Zinc 1,6-Fructose Diphosphate (Linear Form) Dihydroxyacetone phosphate 1,6-DI-O-PHOSPHONO-D-MANNITOL N-(4-CHLOROPHENYL)-3-(PHOSPHONOOXY)NAPHTHALENE-2-CARBOXAMIDE Artenimol Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2 Tucatinib	Diseases 1	Diseases 2
Novel Novel	Symbols APP and IFIH1	Name 1 amyloid beta precursor protein	Name2 interferon induced with helicase C domain 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 DDX58/IFIH1-mediated induction of interferon-alpha/beta Ub-specific processing proteases Ovarian tumor domain proteases TRAF3-dependent IRF activation pathway TRAF6 mediated IRF7 activation TRAF6 mediated NF-kB activation TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 Negative regulators of DDX58/IFIH1 signaling Negative regulators of DDX58/IFIH1 signaling SARS-CoV-1 activates/modulates innate immune responses SARS-CoV-2 activates/modulates innate and adaptive immune responses Evasion by RSV of host interferon responses Modulation of host responses by IFN-stimulated genes	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Type I diabetes mellitus
Novel Novel	Symbols APP and CDKN2B	Name 1 amyloid beta precursor protein	Name2 cyclin dependent kinase inhibitor 2B	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Type II diabetes mellitus Osteosarcoma Malignant pleural mesothelioma
Novel Novel	Symbols APP and INS	Name 1 amyloid beta precursor protein	Name2 insulin	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Regulation of gene expression in beta cells Insulin processing Insulin processing Synthesis, secretion, and deacylation of Ghrelin Regulation of insulin secretion COPI-mediated anterograde transport PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes NPAS4 regulates expression of target genes Amyloid fiber formation	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 Glisoxepide Zinc M-Cresol Myristic acid Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Permanent neonatal diabetes mellitus (PNDM) Type I diabetes mellitus Maturity onset diabetes of the young (MODY)
Novel Novel	Symbols APP and PPARG	Name 1 amyloid beta precursor protein	Name2 peroxisome proliferator activated receptor gamma	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Regulation of PTEN gene transcription Regulation of PTEN gene transcription MECP2 regulates transcription factors Transcriptional regulation of brown and beige adipocyte differentiation by EBF2	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 alpha-Linolenic acid Icosapent Troglitazone Mesalazine Valproic acid Indomethacin Rosiglitazone Fenoprofen Nateglinide Clofazimine Repaglinide Telmisartan Balsalazide Ibuprofen Glipizide Amiodarone Pioglitazone Mitiglinide Bezafibrate Flufenamic acid Resveratrol Phthalic Acid Capric acid Doconexent Oleic Acid (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID Reglitazar Elafibranor AMG-131 CLX-0921 Muraglitazar Ertiprotafib Ragaglitazar Tesaglitazar (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid 9(S)-HODE difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID 3-(5-methoxy-1H-indol-3-yl)propanoic acid Indeglitazar (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid 2-chloro-5-nitro-N-phenylbenzamide (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE Triclosan (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid Aleglitazar Clinofibrate Cannabidiol Lobeglitazone Ciglitazone Dexibuprofen Omega-3 fatty acids Curcumin Arhalofenate Isoflavone Naveglitazar Fenofibric acid Fish oil Medical Cannabis Nabiximols Darglitazone Curcumin sulfate	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Thyroid cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Type II diabetes mellitus
Novel Novel	Symbols APLP1 and HLA-DQA1	Name 1 amyloid beta precursor like protein 1	Name2 major histocompatibility complex, class II, DQ alpha 1	Pathway 1	Pathway 2 Downstream TCR signaling Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules MHC class II antigen presentation Co-inhibition by PD-1 Interferon gamma signaling	Drugs 1 Zinc Copper Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1	Diseases 2 Systemic lupus erythematosus Graves' disease Hashimoto's thyroiditis Dilated cardiomyopathy (DCM) Type I diabetes mellitus
Novel	Symbols TCTN2 and COQ5	Name 1 tectonic family member 2	Name2 coenzyme Q5, methyltransferase	Pathway 1 Anchoring of the basal body to the plasma membrane	Pathway 2 Ubiquinol biosynthesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols IFT80 and OTOL1	Name 1 intraflagellar transport 80	Name2 otolin 1	Pathway 1 Intraflagellar transport Intraflagellar transport	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols PHACTR2 and G3BP2	Name 1 phosphatase and actin regulator 2	Name2 G3BP stress granule assembly factor 2	Pathway 1 Platelet degranulation	Pathway 2 SARS-CoV-2 activates/modulates innate and adaptive immune responses	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CILP2 and NIBAN3	Name 1 cartilage intermediate layer protein 2	Name2 niban apoptosis regulator 3	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FREM2 and NHLRC3	Name 1 FRAS1 related extracellular matrix 2	Name2 NHL repeat containing 3	Pathway 1	Pathway 2 Neutrophil degranulation	Drugs 1	Drugs 2	Diseases 1 Fraser syndrome	Diseases 2
Novel	Symbols DNAH5 and LARGE1	Name 1 dynein axonemal heavy chain 5	Name2 LARGE xylosyl- and glucuronyltransferase 1	Pathway 1	Pathway 2 Defective LARGE causes MDDGA6 and MDDGB6 Matriglycan biosynthesis on DAG1	Drugs 1	Drugs 2	Diseases 1 Primary ciliary dyskinesia, including: Primary ciliary dyskinesia; Kartagener syndrome	Diseases 2 Dystroglycanopathy; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama congenital muscular dystrophy (FCMD); Congenital muscular dystrophy with muscle hypertrophy (MDC1C); Congenital muscular dystrophy with severe intellectual impairment and abnormal glycosylation (MDC1D) Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
Novel	Symbols TMEM127 and LMAN2L	Name 1 transmembrane protein 127	Name2 lectin, mannose binding 2 like	Pathway 1	Pathway 2 COPII-mediated vesicle transport Cargo concentration in the ER	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols TTC9 and SMOC1	Name 1 tetratricopeptide repeat domain 9	Name2 SPARC related modular calcium binding 1	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols NKX6-3 and IDO2	Name 1 NK6 homeobox 3	Name2 indoleamine 2,3-dioxygenase 2	Pathway 1	Pathway 2 Tryptophan catabolism	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols LVRN and FAM170A	Name 1 laeverin	Name2 family with sequence similarity 170 member A	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ZNF799 and TIMM29	Name 1 zinc finger protein 799	Name2 translocase of inner mitochondrial membrane 29	Pathway 1 Generic Transcription Pathway	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols WSCD2 and CKAP4	Name 1 WSC domain containing 2	Name2 cytoskeleton associated protein 4	Pathway 1	Pathway 2 Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Surfactant metabolism Neutrophil degranulation Post-translational protein phosphorylation RND3 GTPase cycle RND2 GTPase cycle	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols GCK and PFKFB2	Name 1 glucokinase	Name2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2	Pathway 1 Regulation of Glucokinase by Glucokinase Regulatory Protein Regulation of gene expression in beta cells Defective GCK causes maturity-onset diabetes of the young 2 (MODY2) Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) Glycolysis FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	Pathway 2 Regulation of glycolysis by fructose 2,6-bisphosphate metabolism	Drugs 1 Beta-D-Glucose 2-amino-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide 3-[(4-fluorophenyl)sulfanyl]-N-(4-methyl-1,3-thiazol-2-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide 2-(methylamino)-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide 2-AMINO-4-FLUORO-5-[(1-METHYL-1H-IMIDAZOL-2-YL)SULFANYL]-N-(1,3-THIAZOL-2-YL)BENZAMIDE	Drugs 2	Diseases 1 Permanent neonatal diabetes mellitus (PNDM) Maturity onset diabetes of the young (MODY)	Diseases 2
Novel	Symbols GATA2 and HHEX	Name 1 GATA binding protein 2	Name2 hematopoietically expressed homeobox	Pathway 1 RUNX1 regulates transcription of genes involved in differentiation of HSCs Transcriptional regulation of granulopoiesis Factors involved in megakaryocyte development and platelet production	Pathway 2 Developmental Lineage of Multipotent Pancreatic Progenitor Cells	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Type II diabetes mellitus
Novel	Symbols ALDOA and ERBB3	Name 1 aldolase, fructose-bisphosphate A	Name2 erb-b2 receptor tyrosine kinase 3	Pathway 1 Platelet degranulation Neutrophil degranulation Glycolysis Gluconeogenesis	Pathway 2	Drugs 1 Zinc 1,6-Fructose Diphosphate (Linear Form) Dihydroxyacetone phosphate 1,6-DI-O-PHOSPHONO-D-MANNITOL N-(4-CHLOROPHENYL)-3-(PHOSPHONOOXY)NAPHTHALENE-2-CARBOXAMIDE Artenimol Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2 Tucatinib	Diseases 1	Diseases 2
Novel	Symbols APP and IFIH1	Name 1 amyloid beta precursor protein	Name2 interferon induced with helicase C domain 1	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 DDX58/IFIH1-mediated induction of interferon-alpha/beta Ub-specific processing proteases Ovarian tumor domain proteases TRAF3-dependent IRF activation pathway TRAF6 mediated IRF7 activation TRAF6 mediated NF-kB activation TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 Negative regulators of DDX58/IFIH1 signaling Negative regulators of DDX58/IFIH1 signaling SARS-CoV-1 activates/modulates innate immune responses SARS-CoV-2 activates/modulates innate and adaptive immune responses Evasion by RSV of host interferon responses Modulation of host responses by IFN-stimulated genes	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Type I diabetes mellitus
Novel	Symbols APP and CDKN2B	Name 1 amyloid beta precursor protein	Name2 cyclin dependent kinase inhibitor 2B	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Type II diabetes mellitus Osteosarcoma Malignant pleural mesothelioma
Novel	Symbols APP and INS	Name 1 amyloid beta precursor protein	Name2 insulin	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 Regulation of gene expression in beta cells Insulin processing Insulin processing Synthesis, secretion, and deacylation of Ghrelin Regulation of insulin secretion COPI-mediated anterograde transport PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes NPAS4 regulates expression of target genes Amyloid fiber formation	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 Glisoxepide Zinc M-Cresol Myristic acid Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Permanent neonatal diabetes mellitus (PNDM) Type I diabetes mellitus Maturity onset diabetes of the young (MODY)
Novel	Symbols APP and PPARG	Name 1 amyloid beta precursor protein	Name2 peroxisome proliferator activated receptor gamma	Pathway 1 Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Pathway 2 PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Regulation of PTEN gene transcription Regulation of PTEN gene transcription MECP2 regulates transcription factors Transcriptional regulation of brown and beige adipocyte differentiation by EBF2	Drugs 1 Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Drugs 2 alpha-Linolenic acid Icosapent Troglitazone Mesalazine Valproic acid Indomethacin Rosiglitazone Fenoprofen Nateglinide Clofazimine Repaglinide Telmisartan Balsalazide Ibuprofen Glipizide Amiodarone Pioglitazone Mitiglinide Bezafibrate Flufenamic acid Resveratrol Phthalic Acid Capric acid Doconexent Oleic Acid (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID Reglitazar Elafibranor AMG-131 CLX-0921 Muraglitazar Ertiprotafib Ragaglitazar Tesaglitazar (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid 9(S)-HODE difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID 3-(5-methoxy-1H-indol-3-yl)propanoic acid Indeglitazar (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid 2-chloro-5-nitro-N-phenylbenzamide (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE Triclosan (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid Aleglitazar Clinofibrate Cannabidiol Lobeglitazone Ciglitazone Dexibuprofen Omega-3 fatty acids Curcumin Arhalofenate Isoflavone Naveglitazar Fenofibric acid Fish oil Medical Cannabis Nabiximols Darglitazone Curcumin sulfate	Diseases 1 Alzheimer's disease (AD)	Diseases 2 Thyroid cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Type II diabetes mellitus
Novel	Symbols APLP1 and HLA-DQA1	Name 1 amyloid beta precursor like protein 1	Name2 major histocompatibility complex, class II, DQ alpha 1	Pathway 1	Pathway 2 Downstream TCR signaling Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules MHC class II antigen presentation Co-inhibition by PD-1 Interferon gamma signaling	Drugs 1 Zinc Copper Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1	Diseases 2 Systemic lupus erythematosus Graves' disease Hashimoto's thyroiditis Dilated cardiomyopathy (DCM) Type I diabetes mellitus

Page 4 out of 58 pages

Search Results : Diabetes